141 related articles for article (PubMed ID: 14964916)
1. Scientists mine for genetic sources of cancer.
Vickery K
Provider; 2004 Feb; 30(2):20-3, 27-8, 33. PubMed ID: 14964916
[No Abstract] [Full Text] [Related]
2. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
3. Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics.
Tolliday N; Clemons PA; Ferraiolo P; Koehler AN; Lewis TA; Li X; Schreiber SL; Gerhard DS; Eliasof S
Cancer Res; 2006 Sep; 66(18):8935-42. PubMed ID: 16982730
[TBL] [Abstract][Full Text] [Related]
4. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
5. The NCI Developmental Therapeutics Program.
Collins JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
[No Abstract] [Full Text] [Related]
6. Big money for cancer genomics.
Check E
Nature; 2005 Dec; 438(7070):894. PubMed ID: 16355172
[No Abstract] [Full Text] [Related]
7. The discovery and development of new antileukemic drugs.
Grever M; Malspeis L
Hematol Oncol Clin North Am; 1993 Feb; 7(1):233-54. PubMed ID: 8449860
[TBL] [Abstract][Full Text] [Related]
8. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
[No Abstract] [Full Text] [Related]
9. An open letter to cancer researchers.
Elledge SJ; Hannon GJ
Science; 2005 Oct; 310(5747):439-41. PubMed ID: 16239460
[No Abstract] [Full Text] [Related]
10. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
DeVita VT
Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433
[No Abstract] [Full Text] [Related]
11. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
Sheikh N
Curr Opin Mol Ther; 2003 Aug; 5(4):428-32. PubMed ID: 14513687
[TBL] [Abstract][Full Text] [Related]
12. Clinical testing of drugs for cancer in the United States and the Soviet Union.
Holland JF
Natl Cancer Inst Monogr; 1977 Mar; (45):261-2. PubMed ID: 927493
[No Abstract] [Full Text] [Related]
13. Technology transfer: U.S. scientists faulted on biotech consulting.
Kaiser J
Science; 2004 May; 304(5675):1222. PubMed ID: 15166331
[No Abstract] [Full Text] [Related]
14. [Past and current problems in tumor research].
von Wasielewski E; Sedlacek HH
Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
[No Abstract] [Full Text] [Related]
15. A review of the report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee.
Richardson AP
Cancer Treat Rep; 1984 Jan; 68(1):340-1. PubMed ID: 6692434
[No Abstract] [Full Text] [Related]
16. The linear array.
Zubrod CG; Schepartz SA; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):13-4. PubMed ID: 927488
[No Abstract] [Full Text] [Related]
17. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
18. Cancer problems lead list for potential medical marijuana research studies.
Smigel K
J Natl Cancer Inst; 1997 Sep; 89(17):1255. PubMed ID: 9293912
[No Abstract] [Full Text] [Related]
19. Collection and presentation of combination data.
Mancher RR
Cancer Chemother Rep 2; 1974 Mar; 4(1):167-80. PubMed ID: 4826496
[No Abstract] [Full Text] [Related]
20. Orphan products activities of the National Institutes of Health.
Schepartz SA
Prog Clin Biol Res; 1983; 127():173-86. PubMed ID: 6889399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
